In the first quarter of 2017, the news of the 2016 annual report of the pharmaceutical network on June 1 was just over. According to statistics, in the first quarter with a total of seven drug companies net profit of more than 500 million yuan, among them, the sig pharmaceutical industry with 1.068 billion yuan in the first place, and only a net income reached 1 billion drug firms; Shanghai pharma followed with 999 million yuan, while hengrui pharmaceuticals had the highest gross margin of 86.80 percent. 

 

In the first quarter of 2017, the net profit was 500 million yuan ($100 million). 

 

 

conus 

 

Major financial data for the first quarter of 2017 in kangmei pharmaceutical co. (unit: yuan) 

 

Data source: the first quarter of 2017 in the pharmaceutical industry 

 

Sig pharmaceutical hold "Internet +" and "healthy China" two strategic opportunity, intension and extension of the collection development, build a new development model of "sig characteristic" of traditional Chinese medicine industry. The company promoted the whole industrial chain of traditional Chinese medicine, using the Internet thinking, the layout "big health + big platform + big data + big service" system. 

 

In 2016, the revenue of the pharmaceutical industry was 216.42 billion yuan, and net profit was 33.4 billion yuan, compared with 7155 million yuan in the first quarter of 2017, up 21.56 percent year on year. Net income topped 1 billion yuan, up 7.96 percent year on year. The reasons for the growth of the company's performance are as follows: first, it is the construction of the whole large health industry map layout and the industrial system; Second, we will seize the opportunities of change in the industry and strengthen the status of the leading enterprises of Chinese medicine. Third, we will pay dividends on the private medical policy of the private sector, make medical services in the deep, and take the strategic heights of the great health industry. Fourth, the core value system promotes brand promotion. 

 

In 2017, the development strategy of the health services system built around the full lifecycle of the pharmaceutical industry is driving the company's sustainable development. Through the value of the core value system, the company's brand influence has been greatly promoted. We need to expand the industry and expand the resources of development through cross-cutting. In order to further stimulate the utility of the advantage resources, the product and service should be done fine. As soon as possible to promote chongqing, yunnan, qinghai area signing fall to the ground of the project, accelerate the health service platform, marketing platform construction and the transformation and upgrading, strive to realize the new benefits. 

 

Shanghai medicine 

 

Shanghai pharma's primary financial data for the first quarter of 2017 (unit: yuan) 

 

Data source: Shanghai pharma report in the first quarter of 2017 

 

In the first quarter of this year, the company's operating income was 33129 million yuan, up 13.16 percent year on year. Attributable to shareholders of listed companies net profit of 999 million yuan, up 12.37% from a year earlier, attributable to shareholders of listed companies deducting non-recurring gains and losses net profit of 939 million yuan, up 20.82% from a year earlier. 

 

The operating income of the pharmaceutical manufacturing business was 37.94 billion yuan, up 19.94 percent year on year, and the gross margin was 50.61 percent. Sales of 60 key products amounted to 18.93 billion yuan, up 15.07 percent from a year earlier, accounting for 49.90 percent of industrial sales, with an average gross margin of 69.82 percent. In the key products, there are 26 products that are expected to sell more than 100 million yuan a year. 

 

The operating income of the pharmaceutical distribution business was 29.485 billion yuan, up 12.93 percent year on year and 6.15% in gross margin. 

 

The business revenue of the pharmaceutical retail business was 12.8 billion yuan, up 4.30 percent year on year, and the gross margin was 15.88 percent. 

 

It is worth mentioning that the Shanghai pharmaceutical group medicine holding co., LTD. Xuzhou pharmaceutical co., LTD., xuzhou huaihai pharmaceutical co., LTD. Mergers and acquisitions, basically completed the layout of the company in north jiangsu market; By the transferee guangzhou zhongda industrial group co., LTD. Held in zhongshan medical pharmaceutical co., LTD. 31.593% stake in the continued on stock equity management, enhance the competitiveness of a company in guangdong area. 

 

Henry 

 

The main financial data for the first quarter of 2017 in hengri medicine (unit: yuan) 

 

Data source: the first quarter of 2017 in the pharmaceutical industry 

 

The sales of hengrui pharmaceuticals are market-oriented and customer-centric. Revenue was 110.94 billion yuan in 2016, with a net profit of 25.89 billion yuan. In the first quarter of 2017, the revenue was 31.69 billion yuan, up 18.76 percent year on year and net profit of 86.2 million yuan, up 18.63 percent year on year, and the gross margin was 86.80 percent. The growth of its performance: first, it is to promote the distribution of sales, to segment the market, to improve the management structure of the organization, and to focus on the professional road. The second is to establish academic marketing system, professional sales team building, sales model transformation, gradually formed the academic guiding, direct sales model, innovative medicine sales basis; Third, strengthen personnel to complement, improve the training system and build a quality sales team; Fourth, build the platform of the project, integrate the resources to improve efficiency, and give full play to the advantages of the product. 

 

In 2017, we will adhere to the two strategies of "scientific and technological innovation" and "internationalization". 

 

We will carry out the development strategy of "scientific and technological innovation". We will further increase research and development investment, and invest in r&d investment of 8-10% of our sales revenue each year, and lay a strong material foundation for innovation. At the same time, focus on antitumor drugs, medication, cardiovascular surgery, contrast agent and biological medicine, closely integrate the international advanced level, innovative medicine and branded generics in parallel, the domestic market and foreign market, achieve the virtuous cycle of innovation and development, promote innovation of global sales. 

 

We will vigorously promote the "internationalization" development strategy. With vision of globalization continue to strengthen exchanges and cooperation with multinational pharmaceutical enterprise, gradually set up overseas sales team, to achieve the scale of the generic drugs in global sales basis, as the ultimate realization of patent medicine sales experience of globalization, efforts to make the company in a new round of competition in the global biological medicine. 

 

conclusion 

 

In recent years, the pharmaceutical industry policy, in the short term will cause certain influence to the industry, but in the long run, these policies more conducive to industry's evolution. Enterprises can only make healthy development by improving their core competitiveness by improving their core competitiveness.